The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK
-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs).
The accelerated approval of lorlatinib in this setting is contingent on the results of a confirmatory trial.
Lorlatinib prescribing information. FDA. Accessed November 2, 2018. https://bit.ly/2P6uini.
... to read the full story